Nivolumab shows lasting melanoma recurrence prevention, with long-term safety, in largest-ever CheckMate 238 trial analysis.

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Final results from the pivotal CheckMate 238 trial showed adjuvant nivolumab continues to significantly improve RFS compared with ipilimumab for patients with advanced melanoma, according to data ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Study Overview: Amgen Inc. is conducting a clinical ...

Nivolumab significantly improved median RFS and DMFS compared to ipilimumab in resected stage IIIB to IIIC or IV melanoma patients. The study suggested potential benefits of morning dosing, with ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the ...

Please provide your email address to receive an email when new articles are posted on . The addition of nivolumab to ipilimumab prolonged survival for patients with advanced melanoma. Nivolumab ...

A genetically engineered herpes virus may offer a new and effective treatment for advanced melanoma, providing hope for ...

The FDA's CRL cited the IGNYTE trial's inadequacy and patient heterogeneity as reasons for not supporting RP1's approval. Replimune plans to pursue a Type A meeting to discuss potential accelerated ...

Of 30 patients with resectable stage III melanoma treated with neoadjuvant nivolumab and relatlimab, 87% were alive and 80% remained disease-free after 4 years. Almost every patient who achieved a ...

Replimune Group announced that the U.S. Food and Drug Administration has accepted the resubmission of its Biologics License Application for RP1 in combination with nivolumab, targeting advanced ...